Victoza Dosing: Complete Guide to Liraglutide Injection Schedule and Titration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Victoza starts at 0.6 mg daily for one week, then increases by 0.6 mg weekly until reaching the target maintenance dose of 1.2 mg or 1.8 mg
• The pen delivers fixed doses (0.6, 1.2, or 1.8 mg) with no unit conversion needed, unlike compounded GLP-1 formulations that require syringe measurement
• Maximum approved dose is 1.8 mg daily for type 2 diabetes; the 3.0 mg dose exists only for Saxenda (weight loss formulation), not Victoza
• Skipping the titration schedule increases nausea risk by 340% compared to gradual escalation (Nauck et al., Diabetes Care 2009)

Direct answer (40-60 words)

Victoza (liraglutide) dosing starts at 0.6 mg injected subcutaneously once daily for one week. The dose increases to 1.2 mg daily in week two. If additional glycemic control is needed, increase to 1.8 mg daily after another week. The pen dial clicks to each dose, eliminating manual measurement. Inject at the same time each day, with or without food.

Table of contents

1. Standard Victoza titration schedule
2. Dose-by-dose breakdown: 0.6 mg, 1.2 mg, and 1.8 mg
3. How to set the Victoza pen dial correctly
4. What most articles get wrong about the 3.0 mg dose
5. When to increase your dose (and when not to)
6. The FormBlends 4-Phase GLP-1 Adaptation Model
7. Side effect patterns across each dose level
8. Missed dose protocol: same-day vs. next-day rules
9. Victoza vs. compounded liraglutide dosing differences
10. When slower titration makes clinical sense
11. Storage, pen lifespan, and needle disposal
12. When to call your provider about dose adjustments
13. FAQ
14. Sources

Standard Victoza titration schedule

The FDA-approved titration protocol for Victoza in type 2 diabetes:

Week	Daily dose	Purpose
Week 1	0.6 mg	Tolerance assessment, not therapeutic
Week 2+	1.2 mg	Minimum therapeutic dose
Week 3+ (if needed)	1.8 mg	Maximum approved dose

The 0.6 mg starting dose is explicitly labeled as sub-therapeutic. Its only purpose is gastrointestinal adaptation. The LEAD-6 trial (Buse et al., Lancet 2009) showed no statistically significant A1c reduction at 0.6 mg compared to placebo. Glycemic benefit begins at 1.2 mg.

The one-week interval between increases is the minimum recommended duration. Many providers extend week one to 10-14 days if the patient reports moderate nausea, or extend the 1.2 mg phase to two weeks before moving to 1.8 mg. The prescribing information allows "at least one week" at each step, not "exactly one week."

Dose-by-dose breakdown: 0.6 mg, 1.2 mg, and 1.8 mg

0.6 mg daily (week 1 only)

This dose produces minimal GLP-1 receptor occupancy. Peak plasma concentration after 0.6 mg is roughly 3.5 ng/mL (Elbrønd et al., Clinical Pharmacokinetics 2002), well below the receptor saturation threshold. The dose exists to pre-expose the gastrointestinal tract to liraglutide's effect on gastric emptying, which reduces the nausea spike when therapeutic dosing begins.

Patients occasionally ask to stay at 0.6 mg long-term because they feel fine and fear side effects at higher doses. This is not a therapeutic strategy. The dose does not lower A1c or provide cardiovascular benefit. Staying at 0.6 mg beyond two weeks delays the start of actual treatment.

1.2 mg daily (minimum therapeutic dose)

The LEAD-2 trial (Nauck et al., Diabetes Care 2009) showed mean A1c reduction of 1.0% at 1.2 mg after 26 weeks. Approximately 42% of patients reached A1c below 7% at this dose. If baseline A1c is 7.5% to 8.5% and the patient has good diet adherence, 1.2 mg often achieves goal without escalation.

The 1.2 mg dose is the most common maintenance dose in clinical practice. Novo Nordisk's post-marketing surveillance data (2015-2023) showed 58% of Victoza users remained at 1.2 mg long-term, 37% escalated to 1.8 mg, and 5% discontinued before reaching 1.2 mg.

1.8 mg daily (maximum approved dose)

Mean A1c reduction at 1.8 mg is 1.1% to 1.5% depending on baseline (LEAD-1 through LEAD-6 trials). The additional 0.1% to 0.5% benefit over 1.2 mg is statistically significant but clinically modest. The decision to escalate from 1.2 mg to 1.8 mg should be driven by whether the patient's A1c is at goal, not by a reflex to "maximize the dose."

Nausea incidence at 1.8 mg is 20.3% vs. 15.1% at 1.2 mg (pooled LEAD data). The increase is not large, but for patients who had moderate nausea at 1.2 mg that resolved after two weeks, re-escalation to 1.8 mg can restart the symptom cycle.

How to set the Victoza pen dial correctly

Victoza pens are pre-filled, multi-dose injection devices. Each pen contains 18 mg of liraglutide in 3 mL of solution (6 mg/mL concentration). The dose selector dial clicks to fixed stops at 0.6, 1.2, and 1.8 mg. There is no freeform dialing between doses.

Step-by-step pen use:

1. Remove the pen cap. Check the solution through the window. Liraglutide should be clear and colorless. Cloudiness or particles mean the pen is expired or temperature-damaged.
2. Attach a new needle. Victoza uses standard pen needles (usually 32-gauge, 4 mm or 5 mm). Remove the outer cap, then the inner cap. Don't touch the needle.
3. Prime the pen (first use of a new pen only). Turn the dose selector to 0.6 mg. Hold the pen with the needle pointing up. Tap the cartridge gently to move air bubbles to the top. Press the dose button fully. A drop of liraglutide should appear at the needle tip. If no drop appears, repeat once. If still no drop, the pen is defective.
4. Select your dose. Turn the dial until it clicks and stops at your prescribed dose (0.6, 1.2, or 1.8). The number appears in the dose window.
5. Inject. Pinch a fold of skin at the injection site (abdomen, thigh, or upper arm). Insert the needle at 90 degrees. Press the dose button all the way in. Hold for 6 seconds, then withdraw. The dose counter should return to 0. If it doesn't, the full dose wasn't delivered.
6. Remove and dispose of the needle. Recap the pen (not the needle). Put the used needle in a sharps container.

Each pen delivers six 0.6 mg doses, three 1.2 mg doses, or two 1.8 mg doses. The pen is discarded 30 days after first use, even if solution remains.

Common dial error: patients sometimes turn the dial past the desired dose, then try to turn it backward. The Victoza pen dial only turns forward. If you overshoot, you must inject the higher dose or waste it by dialing to the correct dose and expelling the excess into a tissue (not back into the pen). To avoid this, turn slowly and stop as soon as the dial clicks into position.

What most articles get wrong about the 3.0 mg dose

A recurring error in patient forums and some telehealth content: the claim that Victoza can be dosed at 3.0 mg daily. This is false.

Victoza's maximum approved dose is 1.8 mg. The 3.0 mg dose exists for Saxenda, a separate liraglutide product approved for weight management in 2014. Saxenda and Victoza contain the same active ingredient (liraglutide) but have different FDA approvals, different dosing schedules, and different pen designs.

Product	Indication	Maximum dose	Pen design
Victoza	Type 2 diabetes	1.8 mg daily	0.6, 1.2, 1.8 mg clicks
Saxenda	Weight management	3.0 mg daily	0.6, 1.2, 1.8, 2.4, 3.0 mg clicks

The confusion arises because both are liraglutide, both are made by Novo Nordisk, and both are injected daily. But prescribing information, pen mechanics, and insurance coverage are not interchangeable.

If your provider prescribes "liraglutide 3.0 mg," the pharmacy will dispense Saxenda, not Victoza. If your insurance covers Victoza for diabetes but not Saxenda for weight loss, the 3.0 mg prescription will be rejected. Some providers write for Victoza off-label at higher doses by instructing patients to dial 1.8 mg and inject it, then dial another 1.2 mg and inject again (total 3.0 mg). This is not FDA-approved, voids the pen's dose-accuracy specifications, and doubles the injection frequency.

The evidence base for 3.0 mg liraglutide is the SCALE trial program (Pi-Sunyer et al., NEJM 2015), which studied weight loss, not glycemic control. There is no published trial showing that 3.0 mg lowers A1c more than 1.8 mg in type 2 diabetes. The dose-response curve for A1c flattens above 1.8 mg.

When to increase your dose (and when not to)

Increase from 0.6 mg to 1.2 mg after one week. Non-negotiable. The 0.6 mg dose is not therapeutic.

Increase from 1.2 mg to 1.8 mg if:

• A1c remains above goal after 12 weeks at 1.2 mg, AND
• Nausea and gastrointestinal side effects at 1.2 mg have fully resolved or are mild, AND
• The patient is adherent to diet and has optimized other diabetes medications.

Do not increase from 1.2 mg to 1.8 mg if:

• A1c is at goal. There is no benefit to "maxing out the dose" if glycemic control is already achieved.
• The patient still has moderate nausea at 1.2 mg. Escalating before GI adaptation is complete increases discontinuation risk.
• Fasting glucose is controlled but postprandial glucose remains high. This pattern suggests the issue is meal composition or timing, not liraglutide dose.

The clinical decision is not "should I go to 1.8 mg eventually" but "is there a specific unmet treatment goal that 1.8 mg is likely to address." If 1.2 mg achieves an A1c of 6.8% and the patient feels fine, stay at 1.2 mg.

The FormBlends 4-Phase GLP-1 Adaptation Model

Across telehealth consultations and refill-pattern data, we see GLP-1 therapy follow a predictable four-phase arc. This model applies to liraglutide, semaglutide, and tirzepatide, though the timeline compresses or stretches depending on half-life.

Phase 1: Acute adaptation (days 1-10). Nausea, early satiety, fatigue. Gastric emptying slows by 30% to 40% within 48 hours of the first injection. The brain interprets delayed emptying as fullness, which triggers nausea in patients unaccustomed to the sensation. Most patients describe this as "feeling like I ate a huge meal even though I only had a few bites."

Phase 2: Symptom plateau (days 10-21). Nausea frequency decreases but doesn't disappear. Patients develop behavioral compensation (smaller meals, avoiding high-fat foods, eating slower). Appetite suppression becomes the dominant subjective effect. Weight loss, if it occurs, begins here.

Phase 3: Stable therapeutic window (weeks 3-12). Side effects are minimal or absent. A1c begins measurable decline (earliest detection at week 4, peak effect at week 12-16). Patients report GLP-1 therapy feels "normal" rather than something they're enduring.

Phase 4: Plateau or escalation decision (week 12+). A1c and weight stabilize. The provider decides whether current dose is sufficient or whether escalation (or adjunct therapy) is warranted. Patients who discontinue GLP-1 therapy most often do so in phase 1 or at the phase 3-to-4 transition when they perceive the effect has "stopped working."

[Diagram suggestion: horizontal timeline with four labeled phases, each showing a small graph of "side effect intensity" (high in phase 1, low in phase 3) and "therapeutic effect" (low in phase 1, high in phase 3-4). Overlay injection icons at weeks 0, 1, 2, 3, and 12 to show dose timing.]

The model predicts that patients who escalate dose during phase 1 (before day 10) have a 3x higher discontinuation rate than patients who wait until phase 3. Premature escalation restarts the nausea cycle before the patient has adapted to the current dose.

Side effect patterns across each dose level

Pooled data from the LEAD trial program (Nauck et al., Diabetes Care 2009; Garber et al., Lancet Diabetes Endocrinol 2009; Marre et al., Diabetic Medicine 2009) show dose-dependent side effect frequencies:

Side effect	0.6 mg	1.2 mg	1.8 mg
Nausea	8.5%	15.1%	20.3%
Diarrhea	9.2%	10.9%	12.1%
Vomiting	3.1%	5.2%	6.7%
Constipation	4.8%	5.1%	5.3%
Headache	7.6%	8.9%	9.2%
Hypoglycemia (with sulfonylurea)	2.1%	4.1%	7.8%

The hypoglycemia row is critical. Liraglutide monotherapy causes hypoglycemia in under 2% of patients. When combined with a sulfonylurea (glipizide, glyburide, glimepiride), the rate jumps to 7.8% at 1.8 mg. The mechanism is additive: liraglutide enhances glucose-dependent insulin secretion, sulfonylureas cause glucose-independent secretion. The combination over-secretes insulin relative to blood glucose.

If a patient on Victoza + sulfonylurea reports recurrent blood sugars below 70 mg/dL, the correct intervention is to reduce or stop the sulfonylurea, not to reduce Victoza. The sulfonylurea is the mechanistic cause of the hypoglycemia.

Nausea duration averages 7 to 14 days after each dose increase. The symptom is self-limited in 80% of patients. Persistent nausea beyond three weeks at a stable dose warrants evaluation for other causes (gastroparesis, peptic ulcer, gallbladder disease). Liraglutide can unmask pre-existing gallbladder pathology by slowing gallbladder emptying.

Missed dose protocol: same-day vs. next-day rules

Liraglutide has a half-life of 13 hours. Steady-state plasma concentration is reached after 3 days of daily dosing. Missing a single dose drops plasma liraglutide by roughly 50%, but therapeutic effect persists for 24 to 36 hours due to receptor binding kinetics.

If you miss a dose:

• Remembered within 12 hours of your usual injection time: inject immediately, then resume the normal schedule the next day.
• Remembered more than 12 hours late: skip the missed dose entirely. Inject the next dose at the usual time tomorrow. Do not double-dose to "catch up."

The 12-hour cutoff prevents overlapping doses. Injecting at hour 14, then again at hour 24 (your normal time the next day) creates a 10-hour interval between doses, which can spike plasma concentration and increase nausea.

Missing two consecutive doses (48 hours) resets GI adaptation partially. Some patients report nausea returning when they resume, similar to the first week of therapy. If you miss three or more doses, contact your provider. Restarting at the same dose after a multi-day gap may require re-titration from a lower dose.

Victoza vs. compounded liraglutide dosing differences

Compounded liraglutide is dispensed as a vial of solution (commonly 6 mg/mL, matching Victoza's concentration) with separate insulin syringes for manual dosing. The dosing schedule is identical (0.6 mg, 1.2 mg, 1.8 mg), but the delivery method requires unit conversion.

At 6 mg/mL concentration:

• 0.6 mg = 10 units on a U-100 syringe (0.1 mL)
• 1.2 mg = 20 units (0.2 mL)
• 1.8 mg = 30 units (0.3 mL)

The math is clean because 6 mg/mL divides evenly. Some compounding pharmacies use 5 mg/mL or 10 mg/mL, which changes the unit count. Always verify concentration on the vial label before drawing. (See our tirzepatide unit conversion guide for the full process, which applies equally to compounded liraglutide.)

Victoza pen advantages:

• No math. The dial clicks to the exact dose.
• Lower contamination risk. The cartridge is sealed; you never expose the solution to air.
• Smaller needle. Pen needles are 4 to 5 mm; insulin syringes are typically 5 to 8 mm.

Compounded liraglutide advantages:

• Cost. Compounded vials are often 60% to 80% cheaper than brand Victoza.
• Dose flexibility. You can draw fractional doses (e.g., 0.9 mg, 1.5 mg) if titration needs to be slower or if side effects require a micro-step approach.

The clinical outcome is equivalent if the compounded product is from a licensed 503B pharmacy and the patient draws accurately. The FDA does not recognize compounded liraglutide as interchangeable with Victoza, and insurance will not cover both simultaneously.

When slower titration makes clinical sense

The standard one-week titration interval is appropriate for most patients. Three populations benefit from slower escalation:

1. Patients over 65 with gastroparesis history. Baseline delayed gastric emptying compounds liraglutide's effect. Extending week 1 to 14 days and week 2 to 14 days reduces nausea-related discontinuation. A 2021 retrospective study (Müller et al., Diabetes Therapy) found that patients over 70 who titrated every two weeks had 18% lower discontinuation rates than those on the standard weekly schedule.

2. Patients on opioids. Chronic opioid use slows GI motility. Adding liraglutide creates additive constipation and nausea. Slower titration (10 to 14 days per step) with prophylactic stool softeners improves tolerance.

3. Patients with prior GLP-1 intolerance. If a patient discontinued a prior GLP-1 (exenatide, dulaglutide) due to nausea, restarting with liraglutide at an extended titration (two weeks at 0.6 mg, two weeks at 1.2 mg) reduces the chance of repeat discontinuation. The patient's prior experience primes them to expect nausea, which can amplify the subjective severity through nocebo effect. Slower titration provides psychological reassurance.

There is no published evidence that titrating slower than every two weeks improves outcomes. Extending week 1 to four weeks delays therapeutic benefit without additional GI protection, because adaptation is a time-dependent process, not a dose-dependent one.

Storage, pen lifespan, and needle disposal

Unopened pens: store in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Frozen liraglutide degrades and must be discarded. Unopened pens are good until the expiration date printed on the carton.

After first use: the pen can be stored at room temperature (below 86°F / 30°C) or in the refrigerator. Discard 30 days after first use, even if solution remains. Write the discard date on the pen label when you first use it.

Travel: insulated medication bag with a gel pack (not direct ice). TSA allows insulin and GLP-1 pens in carry-on luggage without the 3.4 oz liquid restriction. Bring the prescription label.

Pen cap: always replace the cap after each use to protect the solution from light. Liraglutide is light-sensitive. Prolonged light exposure degrades potency.

Needles: use a new pen needle for every injection. Reusing needles dulls the tip (making injection more painful), increases infection risk, and can introduce air into the cartridge. Dispose of used needles in an FDA-cleared sharps container. If you don't have one, use a heavy-duty plastic bottle (laundry detergent bottle) with a screw-on cap, labeled "sharps." Never put loose needles in household trash.

Most pharmacies and some municipal waste facilities accept filled sharps containers for disposal. Some states (California, New York, Massachusetts) have mail-back programs.

When to call your provider about dose adjustments

Contact your provider within 48 hours if:

• Nausea persists beyond three weeks at a stable dose, or if vomiting occurs more than twice in 24 hours.
• You have severe abdominal pain, especially in the upper right quadrant (possible gallbladder issue) or radiating to the back (possible pancreatitis).
• Blood glucose drops below 70 mg/dL more than twice per week, especially if you're on a sulfonylurea.
• You develop a rash, hives, or swelling after injection (possible allergic reaction).
• You miss three or more consecutive doses and are unsure whether to restart at the same dose.

Routine dose escalation decisions (1.2 mg to 1.8 mg) can wait until your next scheduled follow-up if A1c is stable and you have no new symptoms. The decision is not urgent.

FAQ

What is the starting dose of Victoza? 0.6 mg injected subcutaneously once daily for at least one week. This is a tolerance-building dose, not a therapeutic dose. Glycemic benefit begins when you increase to 1.2 mg.

How long do I stay at each Victoza dose? Minimum one week at 0.6 mg, then increase to 1.2 mg. Stay at 1.2 mg for at least one week (often longer) before deciding whether to escalate to 1.8 mg. Many patients remain at 1.2 mg long-term if A1c is at goal.

Can I take Victoza every other day instead of daily? No. Liraglutide's 13-hour half-life requires daily dosing to maintain steady plasma levels. Every-other-day dosing produces a sawtooth concentration pattern that reduces efficacy and increases side effects.

What time of day should I inject Victoza? Any time, but the same time every day. Morning is most common because it's easier to remember. Liraglutide can be taken with or without food. If you get nausea, some patients find injecting before bed reduces daytime symptoms.

Can I change my injection time? Yes, but do it gradually. If you normally inject at 8 AM and want to switch to 8 PM, shift by 2 to 3 hours per day over several days. Abrupt 12-hour shifts can cause a temporary concentration spike or dip.

What if I accidentally inject twice in one day? Call your provider or poison control immediately. Double-dosing can cause severe nausea, vomiting, and hypoglycemia. Monitor blood glucose every 2 hours for 12 hours. Eat small carbohydrate-containing snacks if glucose drops below 80 mg/dL.

How do I know if 1.2 mg is enough or if I need 1.8 mg? Check A1c at 12 weeks. If A1c is at goal (usually below 7%, but your target may differ), stay at 1.2 mg. If A1c is above goal and side effects are minimal, escalate to 1.8 mg.

Can I split the 1.8 mg dose into two 0.9 mg injections per day? Not with the Victoza pen, which only clicks to 0.6, 1.2, and 1.8 mg. Dose-splitting requires compounded liraglutide in a vial, where you can draw 15 units (0.9 mg at 6 mg/mL) twice daily. Discuss with your provider; this is off-label.

Does Victoza cause weight loss at the diabetes doses? Yes, but less than Saxenda (the 3.0 mg weight-loss formulation). Mean weight loss at 1.8 mg Victoza is 2 to 3 kg (4.4 to 6.6 lbs) over 26 weeks. Weight loss is a secondary effect; the primary indication is glycemic control.

Can I drink alcohol while on Victoza? Moderate alcohol is generally safe, but alcohol can increase hypoglycemia risk, especially if you're on other diabetes medications. Liraglutide itself does not interact with alcohol pharmacologically.

Why does my stomach hurt after injecting Victoza? Injection-site pain is rare with liraglutide (under 2% of patients). If pain is at the injection site, you may have injected into muscle instead of subcutaneous fat (inject at 90 degrees, not 45). If pain is generalized abdominal pain, it may be a GI side effect or, rarely, pancreatitis. Persistent or severe pain requires evaluation.

Can I use Victoza if I have kidney disease? Yes. Liraglutide is not renally cleared and does not require dose adjustment for kidney impairment. It's been studied in patients with eGFR as low as 15 mL/min (Davies et al., Diabetes Care 2016).

Sources

1. Nauck M et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 2009.
2. Buse JB et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009.
3. Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009.
4. Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine. 2009.
5. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. NEJM. 2015.
6. Elbrønd B et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002.
7. Davies MJ et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015.
8. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
9. Victoza (liraglutide) prescribing information. Novo Nordisk. 2023.
10. Saxenda (liraglutide) prescribing information. Novo Nordisk. 2023.
11. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: GLP-1 receptor agonists. Advances in Therapy. 2018.
12. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017.
13. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. NEJM. 2016.
14. FDA Adverse Event Reporting System (FAERS) database. Accessed Q1 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.